A FINANCIAL PERSPECTIVE ON THE PHARMACEUTICAL INDUSTRY

被引:0
|
作者
Kahraman, Yunus Emre [1 ]
Caliskan, Yilmaz [2 ]
机构
[1] Osmaniye Korkut Ata Univ, Hlth Serv Vocat Sch, Dept Pharm Serv, TR-80000 Osmaniye, Turkiye
[2] Mugla Prov Directorate Environm Urbanizat & Climat, Fethiye Natl Estate Directorate, TR-48300 Mugla, Turkiye
来源
关键词
Pharmaceuticals; Public Health; Finance; Financial Markets; MEDICINES; INCOME;
D O I
10.56782/pps.180
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
As a result of the epidemics in the world in recent years the importance of the health sector has once again emerged and countries have started to invest more in the health sector. In addition to developed countries, underdeveloped and developing countries are investing more in the health sector and technology and governments are trying to control increasing health expenditures. One of the important and dynamic sub-sectors of the health sector is the pharmaceutical sector. States and international companies are investing more in the pharmaceutical sector in order to combat the epidemics in recent years and are conducting more R&D studies by utilizing the developing technology. In this study in the light of the data published by the OECD, it is examined whether there is a similar relationship between the change in the share of health expenditures in the GNP (Gross National Product) of OECD countries between 2010 and 2022 and the change in the size of the pharmaceutical sector in OECD countries. The change in the size of the pharmaceutical sector and the change in the share of health expenditures in GNP have not yielded similar results in each OECD country. It is thought that different factors such as demographic characteristics, geographical location and economic conditions of countries should be taken into consideration when evaluating the relationship between these two variables.
引用
收藏
页码:23 / 31
页数:9
相关论文
共 50 条
  • [31] Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective
    Findlay, JWA
    Smith, WC
    Lee, JW
    Nordblom, GD
    Das, I
    DeSilva, BS
    Khan, MN
    Bowsher, RR
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2000, 21 (06) : 1249 - 1273
  • [33] A PHARMACEUTICAL-INDUSTRY PERSPECTIVE ON DRUG LABELING
    ROBINSON, DS
    PSYCHOPHARMACOLOGY BULLETIN, 1994, 30 (01) : 23 - 25
  • [34] The pharmaceutical industry perspective on pharmacoeconomics in Saudi Arabia
    Alsultan, M.
    Alhokail, M.
    VALUE IN HEALTH, 2006, 9 (06) : A209 - A209
  • [35] Pharmacoeconomics in the new millennium - A pharmaceutical industry perspective
    Thwaites, R
    Townsend, RJ
    PHARMACOECONOMICS, 1998, 13 (02) : 175 - 180
  • [36] A UNIVERSITY PERSPECTIVE ON PHARMACEUTICAL AND INDUSTRY SUPPORT OF RESEARCH
    HOPPIN, ME
    AMERICAN JOURNAL OF CLINICAL NUTRITION, 1987, 46 (01): : 226 - 228
  • [37] Commentary: Epidemiology and the pharmaceutical industry: an inside perspective
    Haas, Joanna
    INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2008, 37 (01) : 53 - 55
  • [38] Looking at CER from the Pharmaceutical Industry Perspective
    Dubois, Robert W.
    JOURNAL OF MANAGED CARE PHARMACY, 2012, 18 (04): : S9 - S12
  • [39] Bangladesh Pharmaceutical Industry: Perspective and the Prospects Introduction
    Islam, S.
    Rahman, A.
    Al-Mahmood, A. K.
    BANGLADESH JOURNAL OF MEDICAL SCIENCE, 2018, 17 (04): : 519 - 525
  • [40] Facets of technology transfer: A perspective of pharmaceutical industry
    Janodia, Manthan D.
    Sreedhar, D.
    Ligade, Virendra S.
    Pise, Ajay
    Udupa, N.
    JOURNAL OF INTELLECTUAL PROPERTY RIGHTS, 2008, 13 (01): : 28 - 34